BridgeBio Pharma Inc. (BBIO), a biopharmaceutical company focused on genetic diseases, is stepping into a season of high-stakes milestones, where science, strategy, and timing converge. Over the next few months, the company will unveil topline data from three registrational Phase 3 trials, each targeting a distinct rare disease with limited treatment options.
The first arrives on Monday, October 27, when interim results from the FORTIFY study will shed light on BBP-418's potential in Limb-girdle Muscular Dystrophy Type 2I/R9.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com